geroprobПроблемы геронаукиProblems of Geroscience2949-47452949-4753АНО «ОСО ИТЕМ»10.37586/2949-4745-3-2023-134-142geroprob-11Research ArticleОбзорыReviewsПоловые и возрастные различия пациентов с хронической сердечной недостаточностьюAge and Sex Differences in Patients with Chronic Heart Failurehttps://orcid.org/0000-0002-2847-4422БродовскаяТ. О.BrodovskayaT. O.

Бродовская Татьяна Олеговна, д-р. мед. наук, доцент, и.о. заведующего кафедрой пропедевтики внутренних болезней

Екатеринбург

Brodovskaya Tatyana O., MD, PhD, professor, Associate Professor, Head of the Department of Propaedeutics of Internal Diseases

Ekaterinburg

tbrod80@gmail.comhttps://orcid.org/0000-0001-5200-9662ВшивцевК. С.VshivtsevK. S.

Вшивцев Кирилл Сергеевич, врач по медицинской профилактике

Екатеринбург

Vshivtsev Kirill S., Preventive medicine physician

Ekaterinburg

vshivtsev.k.12@gmail.comУральский государственный медицинский университетРоссияUral State Medical UniversityRussian FederationЦентральная городская клиническая больница №6РоссияCentral City Clinical Hospital №6Russian Federation20233010202303134142Copyright © Бродовская Т.О., Вшивцев К.С., 20242024Бродовская Т.О., Вшивцев К.С.Brodovskaya T.O., Vshivtsev K.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.geronauka.com/jour/article/view/11

Возрастающее бремя заболеваемости хронической сердечной недостаточностью пациентов пожилого и старческого возраста, появление новых сведений о половых различиях течения данной патологии определяют необходимость обзора существующих данных по указанной проблеме.

Цель работы

Цель работы. Систематизация актуальных данных о половых различиях хронической сердечной недостаточности, в том числе среди пациентов пожилого и старческого возраста.

Материалы и методы

Материалы и методы. Проведен поиск литературных источников за 2011– 2023 годы в базах данных PubMed, Cochrane Library, Embase, GoogleScholar, eLibrary. Критериями включения являлись данные о половозрастных различиях в течении хронической сердечной недостаточности. Предпочтительными языками были русский и английский. В ходе первоначального поиска было найдено 4228 источников. Отобраны полнотекстные публикации в рецензируемых изданиях с результатами рандомизированных и нерандомизированных клинических исследований, мета-анализов и систематических обзоров, одномоментных исследований.

Результаты и обсуждение

Результаты и обсуждение. Охарактеризованы половые различия факторов риска, эпидемиологии, патофизиологии, клинических проявлений, лечения хронической сердечной недостаточности (ХСН), в том числе среди пациентов пожилого и старческого возраста. Представлены сведения, доказывающие необходимость дифференцированного подхода в определении тактики ведения пациентов разного пола с ХСН.

Заключение

Заключение. Необходима разработка новых научных программ и клинических рекомендаций по дифференцированному ведению пациентов с ХСН, в том числе пожилого и старческого возраста, с целью улучшения прогноза и качества жизни.

Introduction

Introduction. The increasing burden of morbidity from heart failure, which is determined to be an age-related disease, new information about sex differences of this pathology determines the need of reviewing existing data on this problem particularly in older patients. The objective is to systematize data on gender differences in heart failure among older patients.

Materials and methods

Materials and methods. A search of literature for 2011–2023 was conducted in the PubMed, Cochrane Library, Embase, Google Scholar databases, eLibrary. Data on sex and age differences of heart failure was included. The preferred languages were Russian and English. During the initial search, 4,228 sources were found. Full-text peer reviewed journal publications with the results of randomized and non-randomized clinical trials, meta-analyses, systematic reviews, and observational studies were selected.

Results and discussion

Results and discussion. Gender differences in risk factors, epidemiology, pathophysiology, clinical manifestations, treatment of heart failure (HF), particularly in older and oldest-old patients were characterized. Presented information proves the need for a differentiated approach for managing patients of both sex with HF in advanced age.

Conclusion

Conclusion. It is necessary to develop new scientific programs and clinical recommendations for the differentiated management of patients with HF, including older and oldest-old patients in order to improve the prognosis and quality of life.

хроническая сердечная недостаточностьполовые различиявозрастheart failuresex differencesageReferencesTsao CW, Aday AW, Almarzooq ZI et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052Tsao CW, Aday AW, Almarzooq ZI et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052Riccardi M, Sammartino AM, Piepoli M, et al. Heart failure: an update from the last years and a look at the near future. ESC Heart Fail. 2022;9(6):3667–3693. doi: 10.1002/ehf2.14257Riccardi M, Sammartino AM, Piepoli M, et al. Heart failure: an update from the last years and a look at the near future. ESC Heart Fail. 2022;9(6):3667–3693. doi: 10.1002/ehf2.14257Savarese G, Becher PM, Lund LH et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. doi: 10.1093/cvr/cvac013Savarese G, Becher PM, Lund LH et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. doi: 10.1093/cvr/cvac013McDonagh TA, Metra M, Adamo M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. EurJHeartFail. 2022; 24: 4–131. doi: 10.1093/eurheartj/ehab368McDonagh TA, Metra M, Adamo M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. EurJHeartFail. 2022; 24: 4–131. doi: 10.1093/eurheartj/ehab368Лясникова Е.А., Федотов П.А., Трукшина М.А. с соавт. Менеджмент больных с хронической сердечной недостаточностью в Российской Федерации: горизонты и реалии второй декады XXI века. Российский кардиологический журнал. 2021;26(9):4658.Lyasnikova E.A., Fedotov P.A., Trukshina M.A. et al. Management of heart failure patients in Russia: perspectives and realities of the second decade of the XXI century. Russian Journal of Cardiology. 2021;26(9):4658. (In Russ.) doi.org/10.15829/1560-4071-2021-4658Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–3072. doi: 10.1161/01.cir.0000039105.49749.6fLloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–3072. doi: 10.1161/01.cir.0000039105.49749.6fBleumink GS , Knetsch AM , Sturkenboom MC et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614–1619. doi: 10.1016/j.ehj.2004.06.038Bleumink GS , Knetsch AM , Sturkenboom MC et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614–1619. doi: 10.1016/j.ehj.2004.06.038Magnussen C, Niiranen TJ, Ojeda FM et al. Sex-Specific epidemiology of heart failure risk and mortality in europe: results from the BiomarCaRE consortium. JACC Heart Fail. 2019;7:204–213. doi: 10.1016/j.jchf.2018.08.008Magnussen C, Niiranen TJ, Ojeda FM et al. Sex-Specific epidemiology of heart failure risk and mortality in europe: results from the BiomarCaRE consortium. JACC Heart Fail. 2019;7:204–213. doi: 10.1016/j.jchf.2018.08.008Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682–1690. doi: 10.1093/eurjpc/zwaa147Bragazzi NL, Zhong W, Shu J, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28(15):1682–1690. doi: 10.1093/eurjpc/zwaa147Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. CircHeartFail. 2013;6(3):606–619. doi: 10.1161/HHF.0b013e318291329aHeidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. CircHeartFail. 2013;6(3):606–619. doi: 10.1161/HHF.0b013e318291329aMozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38–360. doi: 10.1161/CIR.0000000000000350Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38–360. doi: 10.1161/CIR.0000000000000350Strömberg A, Mårtensson J. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs. 2003;2(1):7–18. doi: 10.1016/S1474-5151(03)00002-1Strömberg A, Mårtensson J. Gender differences in patients with heart failure. Eur J Cardiovasc Nurs. 2003;2(1):7–18. doi: 10.1016/S1474-5151(03)00002-1Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. [2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.)] doi:10.15829/1560-4071-2020-40Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. [2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.)] doi:10.15829/1560-4071-2020-40Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны де­лать. Российский кардиологический журнал. 2016;(8):7–13. doi.org/10.15829/1560-4071-2016-8-7-13Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7–13. (In Russ.) doi.org/10.15829/1560-4071-2016-8-7-13Sillars A, Ho FK, Pell GP, et al. Sex differences in the association of risk factors for heart failure incidence and mortality. Heart. 2020;106:203-212. doi: 10.1136/heartjnl-2019-314878Sillars A, Ho FK, Pell GP, et al. Sex differences in the association of risk factors for heart failure incidence and mortality. Heart. 2020;106:203-212. doi: 10.1136/heartjnl-2019-314878Cesaroni G, Mureddu GF, Agabiti N et al. Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study. BMC Public Health. 2021;21(1):415. doi: 10.1186/s12889-021-10442-3Cesaroni G, Mureddu GF, Agabiti N et al. Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study. BMC Public Health. 2021;21(1):415. doi: 10.1186/s12889-021-10442-3Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34. doi: 10.1016/0002-9149(74)90089-7Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34. doi: 10.1016/0002-9149(74)90089-7He J, Ogden LG, Bazzano LA et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002. doi: 10.1001/archinte.161.7.996He J, Ogden LG, Bazzano LA et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002. doi: 10.1001/archinte.161.7.996Eaton CB, Pettinger M, Rossouw J et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail. 2016;9(10):e002883. doi: 10.1161/CIRCHEARTFAILURE.115.002883Eaton CB, Pettinger M, Rossouw J et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail. 2016;9(10):e002883. doi: 10.1161/CIRCHEARTFAILURE.115.002883Ambikairajah A, Walsh E, Tabatabaei-Jafari H et al. Fat mass changes during menopause: a meta-analysis. Am J Obstet Gynecol. 2019;221:393–409.e50. doi: 10.1016/j.ajog.2019.04.023Ambikairajah A, Walsh E, Tabatabaei-Jafari H et al. Fat mass changes during menopause: a meta-analysis. Am J Obstet Gynecol. 2019;221:393–409.e50. doi: 10.1016/j.ajog.2019.04.023Mehta LS, Watson KE, Barac A et al. Cardiovascular Disease and Breast Cancer: where These Entities Intersect: a Scientific Statement From the American Heart Association. Circulation. 2018;137:e30–e66. doi: 10.1161/CIR.0000000000000556Mehta LS, Watson KE, Barac A et al. Cardiovascular Disease and Breast Cancer: where These Entities Intersect: a Scientific Statement From the American Heart Association. Circulation. 2018;137:e30–e66. doi: 10.1161/CIR.0000000000000556Drafts BC, Twomley KM, D'Agostino RJr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877–885. doi: 10.1016/j.jcmg.2012.11.017Drafts BC, Twomley KM, D'Agostino RJr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877–885. doi: 10.1016/j.jcmg.2012.11.017Chen J, Long JB, Hurria A et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60:2504–2512. doi: 10.1016/j.jacc.2012.07.068Chen J, Long JB, Hurria A et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60:2504–2512. doi: 10.1016/j.jacc.2012.07.068Narayan HK, Finkelman B, French B et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation. 2017;135:1397–1412. doi: 10.1161/CIRCULATIONAHA.116.023463Narayan HK, Finkelman B, French B et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation. 2017;135:1397–1412. doi: 10.1161/CIRCULATIONAHA.116.023463Saiki H, Petersen IA, Scott CG et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017;135:1388–1396. doi: 10.1161/CIRCULATIONAHA.116.025434Saiki H, Petersen IA, Scott CG et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017;135:1388–1396. doi: 10.1161/CIRCULATIONAHA.116.025434Amir E, Seruga B, Niraula S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–1309. doi: 10.1093/jnci/djr242Amir E, Seruga B, Niraula S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–1309. doi: 10.1093/jnci/djr242Bairey Merz CN, Nelson MD, Cheng S et al. Sex differences and the left ventricle: morphology matters. Eur Heart J Cardiovasc Imaging. 2020;21(9):991–993. doi: 10.1093/ehjci/jeaa195Bairey Merz CN, Nelson MD, Cheng S et al. Sex differences and the left ventricle: morphology matters. Eur Heart J Cardiovasc Imaging. 2020;21(9):991–993. doi: 10.1093/ehjci/jeaa195Chandramouli C, Teng T-HK, Tay WT et al. ASIAN-HF Investigators. Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. Eur J Heart Fail. 2019;21(3):297–307. doi: 10.1002/ejhf.1358Chandramouli C, Teng T-HK, Tay WT et al. ASIAN-HF Investigators. Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. Eur J Heart Fail. 2019;21(3):297–307. doi: 10.1002/ejhf.1358Pandey A, Omar W, Ayers C et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018;137(17):1814– 1823. doi: 10.1161/CIRCULATIONAHA.117.031622Pandey A, Omar W, Ayers C et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018;137(17):1814– 1823. doi: 10.1161/CIRCULATIONAHA.117.031622Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e484–e594 doi: 10.1161/HYP.0000000000000066Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e484–e594 doi: 10.1161/HYP.0000000000000066Shah SJ, Lam CSP, Svedlund S et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39:3439–3450. doi: 10.1093/eurheartj/ehy531Shah SJ, Lam CSP, Svedlund S et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39:3439–3450. doi: 10.1093/eurheartj/ehy531Bairey Merz CN, Pepine CJ, Walsh MN et al. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534Bairey Merz CN, Pepine CJ, Walsh MN et al. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation. 2017;135(11):1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534Бродовская Т.О., Аребьев Э.В., Гришина И.Ф.с соавт. Острый коронарный синдром у женщин. Есть ли особенности? Уральский медицинский журнал. 2023;22(4):128–139. doi.org/10.52420/2071-5943-2023-22-4-128-139Brodovskaya T.O., Arebev E.V., Grishina I.F. et al. Acute coronary syndrome in women. Are there any special features? Ural Medical Journal. 2023;22(4):128– 139. (In Russ.) doi.org/10.52420/2071-5943-2023-22-4-128-139Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. IntJHeartFail. 2020;2(3):157–181. doi: 10.36628/ijhf.2020.0004Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. IntJHeartFail. 2020;2(3):157–181. doi: 10.36628/ijhf.2020.0004Dewan P , Rorth R , Jhund PS et al. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol. 2019;73:29–40. doi: 10.1016/j.jacc.2018.09.081Dewan P , Rorth R , Jhund PS et al. Differential impact of heart failure with reduced ejection fraction on men and women. J Am Coll Cardiol. 2019;73:29–40. doi: 10.1016/j.jacc.2018.09.081Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. JAmSocEchocardiogr. 2015;28(1):1–39. doi: 10.1016/j.echo.2014.10.003Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. JAmSocEchocardiogr. 2015;28(1):1–39. doi: 10.1016/j.echo.2014.10.003Bachmann KN, Huang S, Lee H et al. Effect of testosterone on natriuretic peptide levels. J Am Coll Cardiol. 2019;73:1288–96. doi: 10.1016/j.jacc.2018.12.062Bachmann KN, Huang S, Lee H et al. Effect of testosterone on natriuretic peptide levels. J Am Coll Cardiol. 2019;73:1288–96. doi: 10.1016/j.jacc.2018.12.062Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143–157. doi: 10.2165/00003088-200948030-00001Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143–157. doi: 10.2165/00003088-200948030-00001Rosano GM, Lewis B, Agewall S et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J.2015;36:2677–2680Rosano GM, Lewis B, Agewall S et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J.2015;36:2677–2680Jochmann N, Stangl K, Garbe E et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J.2005;26:1585–1595. doi: 10.1093/eurheartj/ehi397Jochmann N, Stangl K, Garbe E et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J.2005;26:1585–1595. doi: 10.1093/eurheartj/ehi397CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35. doi: 10.1056/NEJM198706043162301CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35. doi: 10.1056/NEJM198706043162301RutherfordJD, PfefferMA, MoyeLAetal. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE investigators. Circulation. 1994;90:1731–1738. doi: 10.1161/01.cir.90.4.1731RutherfordJD, PfefferMA, MoyeLAetal. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE investigators. Circulation. 1994;90:1731–1738. doi: 10.1161/01.cir.90.4.1731The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. TheSOLVDinvestigators. N Engl J Med. 1991;325:293– 302. doi: 10.1056/NEJM199108013250501The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. TheSOLVDinvestigators. N Engl J Med. 1991;325:293– 302. doi: 10.1056/NEJM199108013250501ClelandJG, ErhardtL, MurrayG et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study investigators. Eur Heart J. 1997;18:41–51ClelandJG, ErhardtL, MurrayG et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study investigators. Eur Heart J. 1997;18:41–51Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301Santema BT, Ouwerkerk W, Tromp J et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394(10205):1254–1263. doi: 10.1016/S0140-6736(19)31792-1Santema BT, Ouwerkerk W, Tromp J et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394(10205):1254–1263. doi: 10.1016/S0140-6736(19)31792-1Danielson C, Lileikyte G, Ouwerkerk W, S P Lam C, Erlinge D, Teng TK. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9(4):2753–2761. doi: 10.1002/ehf2.13974Danielson C, Lileikyte G, Ouwerkerk W, S P Lam C, Erlinge D, Teng TK. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9(4):2753–2761. doi: 10.1002/ehf2.13974Eugene AR. Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol. 2016 May;5(3):209–215Eugene AR. Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol. 2016 May;5(3):209–215Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. Int J Heart Fail. 2020;2(3):157–181. doi: 10.36628/ijhf.2020.0004Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. Int J Heart Fail. 2020;2(3):157–181. doi: 10.36628/ijhf.2020.0004Lam CSP, Arnott C, Beale AL et al. Sex differences in heart failure. Eur Heart J. 2019;40(47):3859–3868c. doi: 10.1093/eurheartj/ehz835Lam CSP, Arnott C, Beale AL et al. Sex differences in heart failure. Eur Heart J. 2019;40(47):3859–3868c. doi: 10.1093/eurheartj/ehz835Kotecha D, Manzano L, Krum H et al. Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855. doi: 10.1136/bmj.i1855Kotecha D, Manzano L, Krum H et al. Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855. doi: 10.1136/bmj.i1855Harada E,Mizuno Y,Kugimiya F et al. Abstract 13269: GenderDifferenceofBeta-BlockerEffectinPatientsWithHeartFailurePres ervedEjectionFraction. Circulation. 2019;140:A13269Harada E,Mizuno Y,Kugimiya F et al. Abstract 13269: GenderDifferenceofBeta-BlockerEffectinPatientsWithHeartFailurePres ervedEjectionFraction. Circulation. 2019;140:A13269Tamargo J, Caballero R, Delpón E. Sex-related differences in the pharmacological treatment of heart failure. Pharmacol Ther. 2022;229:107891. doi: 10.1016/j.pharmthera.2021.107891Tamargo J, Caballero R, Delpón E. Sex-related differences in the pharmacological treatment of heart failure. Pharmacol Ther. 2022;229:107891. doi: 10.1016/j.pharmthera.2021.107891Merrill M, Sweitzer NK, Lindenfeld J et al. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. JACC Heart Fail. 2019;7(3):228–238. doi: 10.1016/j.jchf.2019.01.003Merrill M, Sweitzer NK, Lindenfeld J et al. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. JACC Heart Fail. 2019;7(3):228–238. doi: 10.1016/j.jchf.2019.01.003Rossello X, Ferreira JP, Pocock SJ et al. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. Eur J Heart Fail. 2020;22(5):834–844. doi: 10.1002/ejhf.1740Rossello X, Ferreira JP, Pocock SJ et al. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. Eur J Heart Fail. 2020;22(5):834–844. doi: 10.1002/ejhf.1740Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5:425–438. doi: 10.1038/nrd2032Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5:425–438. doi: 10.1038/nrd2032van Veldhuisen DJ, Rienstra M, van der Meer P. Value of digoxin in patients with heart failure: new pieces to the puzzle. Eur J Heart Fail. 2018;20(7):1146–1147. doi: 10.1002/ejhf.1200van Veldhuisen DJ, Rienstra M, van der Meer P. Value of digoxin in patients with heart failure: new pieces to the puzzle. Eur J Heart Fail. 2018;20(7):1146–1147. doi: 10.1002/ejhf.1200Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744Rådholm K, Zhou Z, Clemens K et al. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab. 2020;22(2):263–266. doi: 10.1111/dom.13876Rådholm K, Zhou Z, Clemens K et al. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab. 2020;22(2):263–266. doi: 10.1111/dom.13876Rivera FB, Tang VAS, De Luna DV et al. Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis. Am Heart J Plus. 2023;26:100261. doi: 10.1016/j.ahjo.2023.100261Rivera FB, Tang VAS, De Luna DV et al. Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis. Am Heart J Plus. 2023;26:100261. doi: 10.1016/j.ahjo.2023.100261Solomon SD , McMurray JJV , Anand IS et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med.2019;381(17):1609–1620. doi: 10.1056/NEJMoa1908655Solomon SD , McMurray JJV , Anand IS et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med.2019;381(17):1609–1620. doi: 10.1056/NEJMoa1908655Klein L, Grau-Sepulveda MV, Bonow RO et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail. 2011;4(5):589–98. doi: 10.1161/CIRCHEARTFAILURE.110.960484Klein L, Grau-Sepulveda MV, Bonow RO et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail. 2011;4(5):589–98. doi: 10.1161/CIRCHEARTFAILURE.110.960484Lund LH, Braunschweig F, Benson L et al. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail. 2017;19(10):1270–1279. doi: 10.1002/ejhf.781Lund LH, Braunschweig F, Benson L et al. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail. 2017;19(10):1270–1279. doi: 10.1002/ejhf.781Koitabashi N, Kass DA. Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2011;9(3):147–57. doi: 10.1038/nrcardio.2011.172Koitabashi N, Kass DA. Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2011;9(3):147–57. doi: 10.1038/nrcardio.2011.172Kormos RL, Cowger J, Pagani FD et al. The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships. Ann Thorac Surg. 2019;107(2):341–353. doi: 10.1016/j.athoracsur.2018.11.011Kormos RL, Cowger J, Pagani FD et al. The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships. Ann Thorac Surg. 2019;107(2):341–353. doi: 10.1016/j.athoracsur.2018.11.011Blumer V, Mendirichaga R, Hernandez GA et al. Sex-specific outcome disparities in patients receiving continuous-flow left ventricular assist devices: a systematic review and meta-analysis. ASAIOJ. 2018;64:440–449. doi: 10.1097/MAT.0000000000000695Blumer V, Mendirichaga R, Hernandez GA et al. Sex-specific outcome disparities in patients receiving continuous-flow left ventricular assist devices: a systematic review and meta-analysis. ASAIOJ. 2018;64:440–449. doi: 10.1097/MAT.0000000000000695MagnussenC, BernhardtAM, OjedaFM, etal. Gender differences and outcomes in left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support. JH eartLungTransplant.2018;37:61–70. doi: 10.1016/j.healun.2017.06.016MagnussenC, BernhardtAM, OjedaFM, etal. Gender differences and outcomes in left ventricular assist device support: the European Registry for Patients with Mechanical Circulatory Support. JH eartLungTransplant.2018;37:61–70. doi: 10.1016/j.healun.2017.06.016DeFilippis EM, Truby LK, Garan AR et al. Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. JACC Heart Fail. 2019;7(3):250–257. doi: 10.1016/j.jchf.2019.01.008DeFilippis EM, Truby LK, Garan AR et al. Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. JACC Heart Fail. 2019;7(3):250–257. doi: 10.1016/j.jchf.2019.01.008Chambers DC, Cherikh WS, Harhay MO et al. International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1042–1055. doi: 10.1016/j.healun.2019.08.001Chambers DC, Cherikh WS, Harhay MO et al. International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1042–1055. doi: 10.1016/j.healun.2019.08.001Lewis EF, Lamas GA, O'Meara E et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9(1):83– 91. doi: 10.1016/j.ejheart.2006.10.012Lewis EF, Lamas GA, O'Meara E et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9(1):83– 91. doi: 10.1016/j.ejheart.2006.10.012Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402. doi: 10.1056/NEJMoa020265Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402. doi: 10.1056/NEJMoa020265Gerber Y, Weston SA, Redfield MM et al. L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. doi: 10.1001/jamainternmed.2015.0924Gerber Y, Weston SA, Redfield MM et al. L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. doi: 10.1001/jamainternmed.2015.0924Lam CS, Carson PE, Anand IS et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012;5(5):571–8. doi: 10.1161/CIRCHEARTFAILURE.112.970061Lam CS, Carson PE, Anand IS et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012;5(5):571–8. doi: 10.1161/CIRCHEARTFAILURE.112.970061

The authors declare that there are no conflicts of interest present.